INTRODUCTION
============

Alcoholism is a common public health problem. Alcoholic consumption is relatively high in Korea (9.1 L/y per Korean adult in 2015) \[[@b1-kjfm-17-0135]\]. According to the Korea National Health and Nutrition Examination Survey, the overall age-adjusted prevalence of alcohol use disorder in Korean adults was 38.8% in 2009 \[[@b2-kjfm-17-0135]\].

Our hospital has systemic healthcare service program for patients with acute alcoholic intoxication patients (AAIP). AAIP is defined as drunken status patients who were transferred our hospital by regional police officer, ambulance, homeless facilities, other hospital, etc. Mainly AAIP are homeless, found in street and transferred by regional police officer or ambulance. Our 'alcohol detoxification clinics' are consisted of medical staff (emergency medical doctors and nurses), social workers, and public health team. After medical evaluation of AAIP, some AAIP admitted to our hospital for further treatment and other AAIP may transferred to other facilities (hospital or homeless facilities, etc.).

The clinician may have difficulty to take care of AAIP due to lack of medical record or their decreased mentality/consciousness. And AAIP may have high probability of co-morbid disease. The aim of this study was to perform a comprehensive laboratory analysis for these patients to investigate the co-morbid medical problem.

METHODS
=======

1. Patients
-----------

We retrospectively reviewed laboratory findings of AAIP who were transferred to Seoul Metropolitan Dongbu Hospital (an urban public hospital) from January 2017 to June 2017.

2. Laboratory Analysis
----------------------

We analyzed the followings laboratory items: complete blood count (CBC), hemoglobin A1c (HbA1c), C-reactive protein (CRP), albumin, total bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), blood urea nitrogen (BUN), creatinine, amylase, glucose, and creatine phosphokinase (CPK). Hepatitis B surface antigen (HBs Ag)/anti-HBs antibody (anti-HBs Ab), hepatitis C virus antibody (anti-HCV Ab), syphilis screening test-rapid plasma regain test (RPR test), and human immunodeficiency virus antigen/antibody (HIV Ag/Ab) tests were also performed.

Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation and Modification of Diet in Renal Disease (MDRD) equation were used to estimate glomerular filtration rate (eGFR) \[[@b3-kjfm-17-0135]\]. We investigated the prevalence of chronic kidney disease (CKD) stages 3--5 according to generally accepted criteria \[[@b4-kjfm-17-0135]\]. For CKD staging, eGFR of 45--59 mL/min/1.73 m^2^, 30--44 mL/min/1.73 m^2^, 15--29 mL/min/1.73 m^2^, and \<15 mL/min/1.73 m^2^ were classified as CKD stages 3a, 3b, 4, and 5, respectively.

3. Statistical Analysis
-----------------------

Data are presented as mean±standard deviation (SD) for continuous variables (CBC, HbA1c, CRP, AST, ALT, BUN, CPK, etc.) and percentages for categorical variables (HBs Ag/anti-HBs Ab, anti-HCV Ab, RPR test, HIV Ag/Ab, and CKD stage 3--5). We presented eGFR as figure using MDRD and CKD-EPI equation. Statistical analysis was performed using IBM SPSS Statistics ver. 20.0 (IBM Corp., Armonk, NY, USA).

RESULTS
=======

1. Patients
-----------

A total of 160 male patients were enrolled. Their mean age was 52.12 years (range, 32--79 years).

2. Complete Blood Counts
------------------------

Serum CBC results are shown in [Table 1](#t1-kjfm-17-0135){ref-type="table"}. Mean±SD of WBC count was 7.08±2.93×10^9^/L. Fifteen patients showed low WBC count (\<4.0×0^9^/L). Mean±SD of Hb was 13.71±2.00 g/dL. A total of 53 patients (33.1%) had anemia (\<13 g/dL). Sixteen patients (16/160, 10.0%) had macrocytic anemia, with mean corpuscular volume (MCV) \>95 fL. Three patients (3/160, 1.9%) had microcytic anemia (MCV \<80 fL). A total of 33 patients (20.6%) had thrombocytopenia (\<150×0^9^/L).

3. Serum Chemistry
------------------

Serum chemistry results are summarized in [Table 1](#t1-kjfm-17-0135){ref-type="table"}. Mean AST and ALT levels were 92.21±91.48 U/L and 40.41±31.47 U/L, respectively. A total of 93 patients (58.1%) showed elevated AST levels (\>50 U/L) while 47 patients (29.4%) showed elevated ALT levels (\>45 U/L). Twelve patients (12/159, 7.5%) showed low serum albumin levels (\<3.5 g/dL). Twelve patients (12.5%) showed high total bilirubin levels (\>1.5 mg/dL). Six patients (6/27, 22.2%) showed high HbA1c levels (\>7.0%).

4. Chronic Kidney Disease Prevalence
------------------------------------

Two patients had CKD stage 3a and one patient had CKD stage 4 using MDRD or CKD-EPI equation. The prevalence of CKD was 1.9%. Distribution of eGFR is shown in [Figure 1](#f1-kjfm-17-0135){ref-type="fig"}. The eGFR calculated by MDRD was higher than that calculated by CKD-EPI equation.

5. Results of Serologic Assay for HBs Ag, Anti-HBs Ab, Anti-HCV Ab, HIV Ag/Ab, and Syphilis
-------------------------------------------------------------------------------------------

Positive rates of HBs Ag and anti-HBs Ab were 3.5% (5/141) and 48.2% (68/141), respectively ([Tables 2](#t2-kjfm-17-0135){ref-type="table"}, [3](#t3-kjfm-17-0135){ref-type="table"}). Patients aged 60--69 years had the highest positive rate (18.8%, 3/16) for HBs Ag. Those aged 50--59 years and those aged more than 70 years showed relatively low positive rates for anti-HBs Ab (40.0% and 25.0%, respectively). Positive rates of anti-HCV Ab, RPR test and HIV Ag/Ab were 2.2% (3/139), 3.5% (5/143), and 0% (0/142), respectively.

DISCUSSION
==========

Although we could not access medical history of our patients, they might have a high probability of chronic diseases. Their high HbA1c levels suggest that these patients might have diabetes mellitus (DM). Elevated AST/ALT and total bilirubin but low albumin levels suggest chronic liver disease. Macrocytic anemia is commonly found in alcoholic liver disease (70.3%) and non-alcoholic liver disease (23.3%) \[[@b5-kjfm-17-0135]\]. Maruyama et al. \[[@b6-kjfm-17-0135]\] have reported that MCV is significantly correlated with estimated alcohol consumption in a study of 423 consecutive patients with various liver diseases. Fuster et al. \[[@b7-kjfm-17-0135]\] have reported that macrocytic anemia is associated with adverse mortality in patients with alcohol dependence. Thrombocytopenia has been observed in up to 76% of patients with chronic liver disease \[[@b8-kjfm-17-0135]\]. Therefore, our study population has a high probability of having DM and/or chronic liver diseases.

We found a relatively low CKD prevalence (1.9%, 3/160 for CKD stages 3--5 stage) in the present study. Shin et al. \[[@b9-kjfm-17-0135]\] have reported that the prevalence of CKD at stages 3--5 is 2.6%--7.7% in Korean general population. Hall et al. \[[@b10-kjfm-17-0135]\] have reported that 6% of homeless people have CKD stages 3--5 in San Francisco county and city. Maziarz et al. \[[@b11-kjfm-17-0135]\] have reported that the progression rate of end stage renal diseases in homeless people is higher than that in poor but domiciled peers in San Francisco county and city. Data on CKD in Korean homeless or alcoholics are currently unavailable. Further studies are needed.

Surprisingly, we found a low seroprevalence of anti-HBs Ab (overall 48.2%), especially in patients aged over 50 years in this study. Korea national immunization program for hepatitis B virus (HBV) and HBV perinatal transmission prevention program was introduced in 1995 and 2002, respectively \[[@b12-kjfm-17-0135]\]. Therefore, seroprevalence of HBV infection in Korea was gradually decreased \[[@b12-kjfm-17-0135]\]. Adjusted seroprevalence of HBs Ag and anti-HBs Ab in Korea 2009 (among 290,212 people undergoing health check-up examinations) were 4.0% and 73.5%, respectively \[[@b13-kjfm-17-0135]\]. Adjusted seroprevalence of anti-HBs Ab in male and female were 71.6% and 75.4%, respectively \[[@b13-kjfm-17-0135]\]. Adjusted seroprevalence of anti-HBs Ab in 50--59, 60--69, and ≥70 age groups were 76.5%, 73.5%, and 69.1%, respectively \[[@b13-kjfm-17-0135]\]. Seroprevalence of HBs Ag and anti-HBs Ab in homeless people in Seoul (Korea) at 1999 were 5.3% and 58.6%, respectively \[[@b14-kjfm-17-0135]\]. AAIP in our study were found to be more vulnerable to HBV infection than homeless people. Our study suggests the need for vaccination program in AAIP. However, we only analyzed the small number of patients in urban region. Further nationwide studies are needed.

In general, AAIP are transferred to police office or regional hospital emergency department (ED). According to a study of Kim et al. \[[@b15-kjfm-17-0135]\], AAIP might have serious acute diseases such as cardiac ischemia and cerebral hemorrhage/infarction. Therefore, police office is not suitable for care of AAIP. Regional hospital may not want to care AAIP due to financial reason or difficulty in caring for them (lack of consciousness, lack of special medical staff). These AAIP are discharged or transferred to other institutions (non-hospital) several days after receiving fundamental treatment \[[@b15-kjfm-17-0135]\]. Continuous medical service might not be available. Therefore, special program is needed to support these patients.

The limitation of our study was that a relatively small number of cases were enrolled. In addition, there was a lack of medical chart review. We only analyzed laboratory findings due to inappropriate medical records (difficulty in taking medical history).

In summary, AAIP who are transferred to ED have various laboratory abnormalities (anemia, thrombocytopenia) with high probabilities of chronic disease such as DM, CKD and chronic liver diseases. Their low positive rate of anti-HBs Ab might be of significant public healthcare concern. Our data suggest that there is a need for systemic followup and medical service program for these AAIP.
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###### 

Age and serum chemistry/complete blood count results

  Characteristic                     No.   Min    Max     Mean±standard deviation   Abnormal (%)^[\*](#tfn1-kjfm-17-0135){ref-type="table-fn"}^
  ---------------------------------- ----- ------ ------- ------------------------- -------------------------------------------------------------
  Age (y)                            160   32     79      52.12±8.57                \-
  White blood cell (×10^9^/L)        160   2.4    20.9    7.08±2.93                 9.4
  Hemoglobin (g/dL)                  160   6.7    18.9    13.71±2.00                33.1
  Mean cell volume (fL)              160   69.6   116.2   92.06±6.36                28.8
  Platelet (×10^9^/L)                160   40     599     235.00±104.86             20.6
  Albumin (g/dL)                     159   2.6    5.2     4.09±0.46                 7.5
  Total bilirubin (mg/dL)            160   0.2    6.8     0.94±0.75                 12.5
  Aspartate aminotransferase (U/L)   160   15.0   522.0   92.21±91.48               58.1
  Alanine aminotransferase (U/L)     160   6.0    178.0   40.41±31.47               29.4
  Blood urea nitrogen (mg/dL)        160   2.0    51.0    12.01±5.90                6.3
  Creatinine (mg/dL)                 160   0.3    3.6     0.71±0.30                 1.9
  Glucose (mg/dL)                    160   48.0   478.0   127.41±59.90              \-
  Amylase (U/L)                      160   25.0   638.0   84.81±70.02               15.6
  Creatine phosphokinase (U/L)       155   44.0   900.0   257.60±217.51             22.5
  Hemoglobin A1c (%)                 27    3.7    10.1    6.22±1.12                 22.2
  C-reactive protein (mg/dL)         141   0.1    6.4     0.72±1.16                 41.8

Percentage of abnormal (exceed reference rage).

###### 

Results of serologic assay for HBs Ag and anti-HBs Ab

  Age (y)   HBs Ag       Anti-HBs Ab               
  --------- ------------ ------------- ----------- -----------
  30--39    13 (92.9)    1 (7.1)       6 (42.9)    8 (57.1)
  40--49    41 (97.7)    1 (2.3)       18 (42.9)   24 (57.1)
  50--59    65 (100.0)   0             39 (60.0)   26 (40.0)
  60--69    13 (81.2)    3 (18.8)      7 (43.8)    9 (56.2)
  ≥70       4 (100.0)    0             3 (75.0)    1 (25.0)
  Total     136 (96.5)   5 (3.5)       73 (51.8)   68 (48.2)

Values are presented as number (%).

HBs Ag, hepatitis B surface antigen; anti-HBs Ab, anti-HBs antibody.

###### 

Results of HBs Ag and anti-HBs Ab

  HBs Ag     Anti-HBs Ab   
  ---------- ------------- ----
  Negative   68            68
  Positive   5             0

HBs Ag, hepatitis B surface antigen; anti-HBs Ab, anti-HBs antibody.
